Cardiovascular Impact of Diabetes Meds

Course #25-624-


Study Points

  1. Identify emerging trends in drug therapy and their place in patient care practices
  2. List diabetes medications with cardiovascular benefit by reducing major adverse cardiovascular events (MACE) or heart failure hospitalizations.
  3. Discuss considerations for safe use of SGLT2 inhibitors and GLP-1 agonists.

    1 . Which class of diabetes medications has shown cardiovascular benefit by reducing major adverse cardiovascular events (MACE)?
    A) Alpha-glucosidase inhibitors
    B) DPP-4 inhibitors
    C) GLP-1 agonists
    D) Sulfonylureas

    PODCAST

    Click to Review



    2 . Which medication has been shown to reduce heart failure hospitalizations?
    A) Empagliflozin
    B) Exenatide
    C) Glipizide
    D) Pioglitazone

    PODCAST

    Click to Review



    3 . Which complication is associated with giving a GLP-1 agonist too close to a procedure or surgery?
    A) Infection
    B) Low blood pressure
    C) Aspirating food or liquid into the lungs
    D) Diabetic ketoacidosis with normal blood glucose

    PODCAST

    Click to Review